Can-Fite BioPharma Ltd. (CANF)

Oncology Corporate Profile

Stock Performance

2.9100
-0.1300

Company Description

Can-Fite BioPharma is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.

Website: http://www.canfite.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CF-102adenosine receptor agonistHepatocellular carcinoma (HCC)II

View additional information on product candidates here »

Source: http://www.canfite.com

Recent News Headlines

5/29/2017 06:17 pm

5/29/2017 06:17 pm

5/29/2017 06:17 pm

5/29/2017 06:17 pm

5/29/2017 06:17 pm

5/16/2017 12:17 am

5/16/2017 12:17 am

5/16/2017 12:17 am

5/16/2017 12:17 am

5/16/2017 12:17 am

5/3/2017 12:17 am

5/3/2017 12:17 am

5/3/2017 12:17 am

5/3/2017 12:17 am

5/3/2017 12:17 am

4/25/2017 12:17 am

4/25/2017 12:17 am

4/25/2017 12:17 am

4/25/2017 12:17 am

4/25/2017 12:17 am

Can-Fite Reports 2016 Financial Results & Provides Clinical Update

3/31/2017 11:00 am

[PR Newswire] - PETACH TIKVA, Israel, March 31, 2017 /PRNewswire/ -- Can-Fite BioPharma Ltd . (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...

New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis

2/28/2017 12:00 pm

[PR Newswire] - PETACH TIKVA, Israel, Feb. 28, 2017 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced new data that show its liver disease drug candidate Namodenoson (CF102) prevented liver (hepatic) fibrosis progression in preclinical studies. "These latest study results add to the growing body of data that demonstrate Namodenoson's potential efficacy in combating non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic steatohepatitis (NASH), indications for which there is currently no FDA approved drug. Liver fibrosis is the excessive accumulation of scar tissue resulting from ongoing inflammation.

Can-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis

2/8/2017 12:00 pm

[PR Newswire] - PETACH TIKVA, Israel, Feb. 8, 2017 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today the Company is ready to commence patient enrollment in the second quarter of 2017 in its global Phase III trial of its lead drug candidate Piclidenoson as a first line treatment for rheumatoid arthritis. The required supply of Piclidenoson has already been manufactured and paid. Piclidenoson is being developed as a first line therapy and replacement for the current standard of care, Methotrexate (MTX), the most widely used drug for rheumatoid arthritis.